| Literature DB >> 18566324 |
Susan P Whitman1, Björn Hackanson, Sandya Liyanarachchi, Shujun Liu, Laura J Rush, Kati Maharry, Dean Margeson, Ramana Davuluri, Jing Wen, Tatiana Witte, Li Yu, Chunhui Liu, Clara D Bloomfield, Guido Marcucci, Christoph Plass, Michael A Caligiuri.
Abstract
Posttranslationally modified histones and DNA hypermethylation frequently interplay to deregulate gene expression in cancer. We report that acute myeloid leukemia (AML) with an aberrant histone methyltransferase, the mixed lineage leukemia partial tandem duplication (MLL-PTD), exhibits increased global DNA methylation versus AML with MLL-wildtype (MLL-WT; P = .02). Among the differentially methylated genes, the SLC5A8 tumor suppressor gene (TSG) was more frequently hypermethylated (P = .003). In MLL-PTD(+) cell lines having SLC5A8 promoter hypermethylation, incubation with decitabine activated SLC5A8 expression. Ectopic SLC5A8 expression enhanced histones H3 and H4 acetylation in response to the histone deacetylase inhibitor, valproate, consistent with the encoded protein-SMCT1-short-chain fatty acid transport function. In addition, enhanced cell death was observed in SMCT1-expressing MLL-PTD(+) AML cells treated with valproate. Within the majority of MLL-PTD AML is a mechanism in which DNA hypermethylation silences a TSG that, together with MLL-PTD, can contribute further to aberrant chromatin remodeling and altered gene expression.Entities:
Mesh:
Substances:
Year: 2008 PMID: 18566324 PMCID: PMC2518901 DOI: 10.1182/blood-2008-01-128595
Source DB: PubMed Journal: Blood ISSN: 0006-4971 Impact factor: 22.113